News | November 04, 2025
Gland Pharma reports Q2 FY26 PAT higher at Rs. 184 Cr
Revenue for the quarter rose 5.8% to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal
Revenue for the quarter rose 5.8% to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal
Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO
Apollo has also announced plans to add over 4,300 beds in the next five years with an investment of over Rs. 7,600 crore
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
Shelter Pharma Limited is set to capitalize on the growing demand for natural health products in India
_256_384.jpg)
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
Subscribe To Our Newsletter & Stay Updated
